Trial Profile
A Phase 1, Randomized, Observer-blinded, Single Dose, Placebo Controlled Dosage-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Plasma-Derived Human Butyrylcholinesterase (HuBChE) Administered Intravenously (IV)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2021
Price :
$35
*
At a glance
- Drugs Butyrylcholinesterase (Primary)
- Indications Poisoning
- Focus Adverse reactions
- Sponsors Baxter Healthcare Corporation
- 14 May 2014 New trial record